[HTML][HTML] Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy
F Moradbeygi, Y Ghasemi, AR Farmani… - Biomedicine & …, 2023 - Elsevier
Patients receiving high-dose methotrexate (HDMTX) for malignancies are exposed to
diverse complications, including nephrotoxicity, hepatotoxicity, mucositis, myelotoxicity …
diverse complications, including nephrotoxicity, hepatotoxicity, mucositis, myelotoxicity …
Virus-mimicking nanodrug active crossing of the blood-brain barrier via transcytosis against central nervous system leukemia
X Dong, W Wu, CL Zhang, RH Huang, Q Wen, X Zhang - Nano Today, 2024 - Elsevier
The poor central nervous system leukemia (CNSL) clinical efficacy of conventional doses of
chemotherapy is mainly attributed to the limited permeability of chemotherapy agents …
chemotherapy is mainly attributed to the limited permeability of chemotherapy agents …
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia
RD Harris, OA Taylor, MM Gramatges… - … : The Journal of …, 2024 - Wiley Online Library
Background Methotrexate is an important component of curative therapy in childhood acute
lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate …
lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate …
[HTML][HTML] Acute Neurotoxicity in Children Treated for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: A 10-Year Single-Centre Experience
I Kranjčec, N Rajačić, T Janjić, M Kukuruzović… - Children, 2024 - mdpi.com
Background: Recent advances in childhood acute lymphoblastic leukemia (ALL) and
lymphoblastic lymphoma (LL) management provide higher survival rates at the cost of …
lymphoblastic lymphoma (LL) management provide higher survival rates at the cost of …
Delayed excretion of high‐dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management
JA Belsky, A Chavana, A Banerjee… - Pediatric Blood & …, 2025 - Wiley Online Library
Background Delayed excretion of high‐dose methotrexate (HD‐MTX) in pediatric acute
lymphoblastic leukemia (ALL) can result in significant morbidity. While methotrexate is …
lymphoblastic leukemia (ALL) can result in significant morbidity. While methotrexate is …
Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)‐induced neurotoxicity in childhood acute lymphoblastic …
T Rupakumar, A Sankar… - British Journal of …, 2024 - Wiley Online Library
Methotrexate (MTX), although an indispensable part of contemporary treatment protocols for
childhood acute lymphoblastic leukaemia (ALL)/lymphomas (LBL) in improving outcomes …
childhood acute lymphoblastic leukaemia (ALL)/lymphomas (LBL) in improving outcomes …